Breast Cancer
JZP598-208: A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer.
- Details
ClinicalTrials.gov ID:
NCT07102381
Diagnosis Type:
NA
USOR Number:
- Address
,
P: